The stock price of Veracyte Inc (NASDAQ: VCYT) has surged by 1.84 when compared to previous closing price of 39.07, but the company has seen a -7.94% decline in its stock price over the last five trading sessions. zacks.com reported 2024-12-19 that The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty.
Is It Worth Investing in Veracyte Inc (NASDAQ: VCYT) Right Now?
VCYT has 36-month beta value of 1.71. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VCYT is 76.39M, and currently, short sellers hold a 3.88% ratio of that float. The average trading volume of VCYT on December 20, 2024 was 781.59K shares.
VCYT’s Market Performance
VCYT’s stock has seen a -7.94% decrease for the week, with a 1.51% rise in the past month and a 16.14% gain in the past quarter. The volatility ratio for the week is 4.30%, and the volatility levels for the past 30 days are at 3.96% for Veracyte Inc The simple moving average for the last 20 days is -6.27% for VCYT stock, with a simple moving average of 41.35% for the last 200 days.
Analysts’ Opinion of VCYT
Many brokerage firms have already submitted their reports for VCYT stocks, with Goldman repeating the rating for VCYT by listing it as a “Neutral.” The predicted price for VCYT in the upcoming period, according to Goldman is $37 based on the research report published on December 05, 2024 of the current year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see VCYT reach a price target of $50. The rating they have provided for VCYT stocks is “Outperform” according to the report published on November 15th, 2024.
UBS gave a rating of “Buy” to VCYT, setting the target price at $43 in the report published on October 16th of the current year.
VCYT Trading at 3.89% from the 50-Day Moving Average
After a stumble in the market that brought VCYT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.50% of loss for the given period.
Volatility was left at 3.96%, however, over the last 30 days, the volatility rate increased by 4.30%, as shares surge +2.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.08% upper at present.
During the last 5 trading sessions, VCYT fell by -8.10%, which changed the moving average for the period of 200-days by +74.58% in comparison to the 20-day moving average, which settled at $42.45. In addition, Veracyte Inc saw 44.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VCYT starting from Stapley Marc, who sale 5,590 shares at the price of $43.42 back on Dec 13 ’24. After this action, Stapley Marc now owns 307,345 shares of Veracyte Inc, valued at $242,737 using the latest closing price.
MARC STAPLEY, the Director of Veracyte Inc, proposed sale 5,590 shares at $44.40 during a trade that took place back on Dec 13 ’24, which means that MARC STAPLEY is holding shares at $248,196 based on the most recent closing price.
Stock Fundamentals for VCYT
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.65 for the gross margin
The net margin for Veracyte Inc stands at -0.02. The total capital return value is set at 0.01. Equity return is now at value -0.83, with -0.77 for asset returns.
Currently, EBITDA for the company is -49.41 million with net debt to EBITDA at -18.96. When we switch over and look at the enterprise to sales, we see a ratio of 6.69. The receivables turnover for the company is 8.71for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.08.
Conclusion
To put it simply, Veracyte Inc (VCYT) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
